HER2-low status as a distinct breast cancer subtype: myth or truth? Analysis of the WSG trials WSG-ADAPT-HR+/HER2-, WSG-PlanB, and WSG-ADAPT-TN - Schmidt, Gilda; Gluz, Oleg; Christgen, Matthias; Reinisch, Mattea; Kümmel, Sherko; Nitz, Ulrike; Braun, Michael; Aktas, Bahriye; Lüdtke-Heckenkamp, Kerstin; Forstbauer, Helmut; Grischke, Eva-Maria; Schumacher, Claudia; et al. (Breast cancer research, 2025)
Gesehen am 21.07.2025